Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations

Journal of Thoracic Oncology

Volumn 9, Issue 4, 2014, Pages 456-463

  Gazdar, Adi ^a,b   Robinson, Linda ^c   Oliver, Dwight ^b   Xing, Chao ^a   Travis, William D ^d   Soh, Junichi ^e   Toyooka, Shinichi ^e   Watumull, Lori ^b   Xie, Yang ^c   Kernstine, Kemp ^b   Schiller, Joan H ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

EGFR gene; Germline mutation; Hereditary lung cancer syndrome; Never smoker status; T790M mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; FAMILIAL CANCER; GERMLINE MUTATION; HUMAN; INHERITANCE; LUNG ADENOCARCINOMA; LUNG CANCER; NON SMALL CELL LUNG CANCER; PENETRANCE; PREVALENCE; PRIORITY JOURNAL; SMOKING; ADULT; AGED; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; EPIDEMIOLOGY; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEDIGREE; PROGNOSIS; SYNDROME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEDIGREE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SYNDROME; UNITED STATES; YOUNG ADULT;

EID: 84922276362     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000130     Document Type: Article

References (35)

1. Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009;6:352-366.
2. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007;7:169-181.
3. Shigematsu S, Lin L, Takahashi T, et al. Clinical and biological features associated with Epidermal Growth Factor Receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
4. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS medicine 2005;2:e73.
5. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res 2013;19:2240-2247.
6. Godin-Heymann N, Bryant I, Rivera MN, et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007;67:7319-7326.
7. Suda K, Onozato R, Yatabe Y, et al. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 2009;4:1-4.
8. Regales L, Balak MN, Gong Y, et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007;2:e810.
9. Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007;67:4665-4670.
10. Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009;4:e4576.
11. Rosell R, Moran T, Carcereny E, et al. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol 2010;12:75-80.
12. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 2009;4:e7464.
13. Oxnard GR, Miller VA, Robson ME, et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012;7:1049-1052.
14. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006;12:43-48.
15. Borras E, Jurado I, Hernan I, et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC cancer 2011;11:406.
16. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-7282.
17. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature genetics 2005;37:1315-1316.
18. Girard N, Lou E, Azzoli CG, et al. Analysis of genetic variants in neversmokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res 2010;16:755-763.
19. Prudkin L, Tang X, Wistuba, II. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol 2009;4:139-141.
20. Tibaldi C, Giovannetti E, Vasile E, et al. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol 2011;6:395-396.
21. Travis W, Brambilla E, Noguchi M, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. Journal of Thoracic Oncology 2009;4:244-285.
22. Stellman SD, Takezaki T, Wang L, et al. Smoking and lung cancer risk in American and Japanese men: an international case-control study. Cancer Epidemiol Biomarkers Prev 2001;10:1193-1199.
23. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-478.
24. Yi JH, Huh J, Kim HJ, et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Annals of hematology 2013;92:459-469.
25. Gazdar AF, Minna JD. Multifocal lung cancers-clonality vs field cancerization and does it matter? Journal of the National Cancer Institute 2009;101:541-543.
26. Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol 2006;30: 606-613.
27. Chung JH, Choe G, Jheon S, et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 2009;4:1490-1495.
28. Ashworth M. The pathology of preclinical medullary thyroid carcinoma. Endocr Pathol 2004;15:227-231.
29. Lohmann D. Retinoblastoma. Advances in experimental medicine and biology 2010;685:220-227.
30. Marsh DJ, Gimm O. Multiple endocrine neoplasia: types 1 and 2. Advances in oto-rhino-laryngology 2011;70:84-90.
31. Frank TS. Hereditary cancer syndromes. Arch Pathol Lab Med 2001;125:85-90.
32. Gatalica Z, Torlakovic E. Pathology of the hereditary colorectal carcinoma. Familial cancer 2008;7:15-26.
33. Tsao A, Tang X, Sabloff B, et al. Clinical-pathological characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006;1:231-239.
34. Hirsch FR, Janne PA, Eberhardt WE, et al. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. J Thorac Oncol 2013;8:373-384.
35. Ohashi K, Maruvka YE, Michor F, et al. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-1080.